Nivolumab Preserves Quality of Life and Reduces Symptom Progression in Resectable NSCLC, Study Finds
A groundbreaking Phase III trial reveals that nivolumab maintains quality of life and reduces symptom worsening in patients with resectable non-small cell lung cancer, including those with advanced Stage III N2 disease.
A recent Phase III CheckMate 77T trial has demonstrated that perioperative treatment with nivolumab does not negatively impact health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those diagnosed with Stage III N2 disease. The comprehensive analysis, presented at the 2025 World Conference on Lung Cancer (WCLC), confirms that patients receiving nivolumab alongside chemotherapy before surgery maintain their QoL across various stages of treatment.
The study assessed HRQoL using patient-reported outcome measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual analog scale (VAS). Patients were administered either neoadjuvant nivolumab combined with chemotherapy or a placebo with chemotherapy, followed by surgical resection and additional therapy. Results showed over 90% PRO completion rates in all nodal status groups, indicating consistent engagement and reliable data collection.
Dr. Jonathan Spicer of McGill University Health Center highlighted the significance of these findings, emphasizing that maintaining QoL during and after treatment is essential for long-term success. Notably, among Stage III N2 patients, nivolumab significantly reduced the risk of QoL deterioration compared to placebo, with hazard ratios of 0.50 for NSCLC-SAQ and 0.47 for EQ-5D-3L VAS. These benefits were observed in patients undergoing various surgical procedures, including single lobectomy or complete resection.
This research underscores nivolumab's dual role in extending event-free survival and safeguarding patient well-being in early-stage resectable NSCLC, particularly those at higher risk due to N2 nodal involvement. The findings support the integration of perioperative nivolumab into treatment regimens aimed at both improving clinical outcomes and preserving quality of life.
Source: https://medicalxpress.com/news/2025-09-nivolumab-quality-life-symptom-deterioration.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Maryland Clarifies Confusing COVID-19 Vaccine Rules Amid Federal Policy Changes
Maryland health officials have released new guidance to clarify COVID-19 vaccine eligibility and insurance coverage amidst recent federal policy shifts, ensuring residents continue to have access to vaccination.
Home Accidents Equally Significant as Road Traffic Incidents, New Study Reveals
A groundbreaking study reveals that home accidents are as common and significant as road traffic crashes in low- and middle-income countries, particularly affecting women. The research emphasizes the need for broader injury prevention strategies targeting domestic environments.
Long COVID Patients Use Self-Tracking and Online Support Networks Amid Healthcare Gaps
Many long COVID patients face healthcare dismissals and inadequate support, turning to wearable devices and online groups to manage their symptoms and advocate for care amidst systemic gaps.
New Insights into Differentiating Autism and ADHD for Better Clinical Diagnosis
Recent UC Davis research highlights the overlap between autism and ADHD, emphasizing the importance of accurate early diagnosis for effective treatment and improved outcomes.